---
figid: PMC8310668__oncotarget-12-1470-g009
figtitle: Proposed schema of AZ, SFN, and AZ+SFN targeting the pro-survival pathways
  in BC
organisms:
- NA
pmcid: PMC8310668
filename: oncotarget-12-1470-g009.jpg
figlink: /pmc/articles/PMC8310668/figure/F9/
number: F9
caption: 'Cells. (A) BC cells are in an acidic environment under normal conditions,
  supporting: (1) growth factor stimulation; and (2) activation of the glycolytic
  pathway and migratory/invasive potential. (B) AZ+SFN treatment works to: (1) modulate
  the antioxidant response; (2) decrease 5-HT secretion; and (3) decrease hypoxia,
  making the cell intracellularly more acidic and the extracellular environment more
  alkaline. The pan-inhibition of these pathways and critical components can ultimately
  reduce or abrogate BC cells’ tumorigenic potential. The question marks in B require
  further evidence and study. The images were created with https://biorender.com.
  Abbreviations: AZ: acetazolamide; SFN: sulforaphane; BC: bronchial carcinoma.'
papertitle: 'Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane
  in combination with acetazolamide actively target bronchial carcinoid cancer in
  disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.'
reftext: Reza Bayat Mokhtari, et al. Oncotarget. 2021 Jul 20;12(15):1470-1489.
year: '2021'
doi: 10.18632/oncotarget.28011
journal_title: Oncotarget
journal_nlm_ta: Oncotarget
publisher_name: Impact Journals LLC
keywords: sulforaphane | acetazolamide | bronchial carcinoid tumors | serotonin |
  carbonic anhydrase
automl_pathway: 0.9550467
figid_alias: PMC8310668__F9
figtype: Figure
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
redirect_from: /figures/PMC8310668__F9
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8310668__oncotarget-12-1470-g009.html
  '@type': Dataset
  description: 'Cells. (A) BC cells are in an acidic environment under normal conditions,
    supporting: (1) growth factor stimulation; and (2) activation of the glycolytic
    pathway and migratory/invasive potential. (B) AZ+SFN treatment works to: (1) modulate
    the antioxidant response; (2) decrease 5-HT secretion; and (3) decrease hypoxia,
    making the cell intracellularly more acidic and the extracellular environment
    more alkaline. The pan-inhibition of these pathways and critical components can
    ultimately reduce or abrogate BC cells’ tumorigenic potential. The question marks
    in B require further evidence and study. The images were created with https://biorender.com.
    Abbreviations: AZ: acetazolamide; SFN: sulforaphane; BC: bronchial carcinoma.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Keap1
  - cnc
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - sht
  - Mhc
  - 5-HT1B
  - 5-HT1A
  - 5-HT2A
  - Pc
  - Akt
  - CAH9
  - casp
  - par
  - para
  - par-6
  - de
  - shi
  - tgo
  - sima
  - ww
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - tor
  - Tor
  - Egfr
  - gcl
  - Gclc
  - GstS1
  - GstE12
  - GstD1
  - GstD2
  - GstD3
  - GstD4
  - GstD5
  - GstD6
  - GstD7
  - GstD8
  - 'On'
  - GABPA
  - NFE2L2
  - KEAP1
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - ITK
  - SLC22A3
  - PC
  - AKT1
  - AKT2
  - AKT3
  - CA9
  - ZNF35
  - CUX1
  - CYTIP
  - CRTAP
  - NR1I2
  - JTB
  - INPP5D
  - SETD2
  - SFN
  - REXO2
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - RORC
  - HIF1A
  - GCLC
  - GCA
  - GMCL1
  - GMCL2
  - SLCO6A1
  - GSTK1
  - GSTA1
  - GSTA2
  - GSTA3
  - GSTA4
  - GSTA5
  - GSTM1
  - GSTM2
  - GSTM3
  - GSTM4
  - GSTM5
  - GSTO1
  - GSTO2
  - GSTP1
  - GSTT1
  - GSTT2
  - GSTZ1
  - GSTT2B
---
